These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33396700)

  • 41. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
    Köhler C; Tittl L; Marten S; Naue C; Spindler M; Stannek L; Fache K; Beyer-Westendorf J
    Thromb Res; 2022 Jul; 215():37-40. PubMed ID: 35623105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Wang Y; Li L; Wei Z; Lu S; Liu W; Zhang J; Feng J; Wang D
    Medicines (Basel); 2023 Jan; 10(1):. PubMed ID: 36662497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study.
    Hohmann C; Lutz M; Vignali S; Borchert K; Seidel K; Braun S; Baldus S; Näbauer M
    Thromb J; 2022 Jul; 20(1):37. PubMed ID: 35787710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C; Tellor KB; Armbruster AL
    Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol.
    Bhat Y; Dixit A; Mistri A; Patel B; Quoraishi SH; Uprichard J
    BMC Neurol; 2019 Nov; 19(1):306. PubMed ID: 31783738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
    Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
    Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Very low-intensity anticoagulant therapy in elderly cardioembolic stroke patients with nonvalvular atrial fibrillation].
    Nagao T; Hamamoto M; Kanda A; Miyazaki T; Terashi A
    Nihon Ronen Igakkai Zasshi; 1994 Sep; 31(9):711-5. PubMed ID: 7823406
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study.
    Paciaroni M; Agnelli G; Falocci N; Tsivgoulis G; Vadikolias K; Liantinioti C; Chondrogianni M; Bovi P; Carletti M; Cappellari M; Zedde M; Ntaios G; Karagkiozi E; Athanasakis G; Makaritsis K; Silvestrelli G; Lanari A; Ciccone A; Putaala J; Tomppo L; Tatlisumak T; Abdul-Rahim AH; Lees KR; Alberti A; Venti M; Acciarresi M; D'Amore C; Becattini C; Mosconi MG; Cimini LA; Soloperto R; Masotti L; Vannucchi V; Lorenzini G; Tassi R; Guideri F; Acampa M; Martini G; Sohn SI; Marcheselli S; Mumoli N; De Lodovici ML; Bono G; Furie KL; Tadi P; Yaghi S; Toni D; Letteri F; Tassinari T; Kargiotis O; Lotti EM; Flomin Y; Mancuso M; Maccarrone M; Giannini N; Bandini F; Pezzini A; Poli L; Padovani A; Scoditti U; Denti L; Consoli D; Galati F; Sacco S; Carolei A; Tiseo C; Gourbali V; Orlandi G; Giuntini M; Chiti A; Giorli E; Gialdini G; Corea F; Ageno W; Bellesini M; Colombo G; Monaco S; Maimone Baronello M; Karapanayiotides T; Caso V
    J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29220330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anticoagulation Protocol for Secondary Prevention of Acute Ischemic Stroke Associated with Nonvalvular Atrial Fibrillation.
    Kimura T; Tucker A; Nakagaki A; Sugimura T; Fukuda S; Katsuno M; Fujita T; Izumi N; Suzuki N; Sako K
    J Stroke Cerebrovasc Dis; 2021 Aug; 30(8):105893. PubMed ID: 34107414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Confidence in the Use of Direct Oral Anticoagulants in the Acute Phase of Nonvalvular Atrial Fibrillation-Related Ischemic Stroke Over the Years: A Real-World Single-Center Study.
    Moroni F; Masotti L; Vannucchi V; Chiarelli R; Seravalle C; Pesci A; Pallini F; Puliti S; Cimolato B; Fattorini L; Scerra C; Ristori F; Imbalzano ML; Spolveri S; Landini G; Grifoni E; Paciaroni M
    J Stroke Cerebrovasc Dis; 2018 Jan; 27(1):76-82. PubMed ID: 28918086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease.
    Fukamachi D; Okumura Y; Matsumoto N; Tachibana E; Oiwa K; Ichikawa M; Haruta H; Nomoto K; Arima K; Hirayama A
    J Interv Cardiol; 2022; 2022():5905022. PubMed ID: 36619818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy.
    Yasaka M; Yokota H; Suzuki M; Yamane T; Ono Y
    Cardiol Ther; 2020 Jun; 9(1):189-199. PubMed ID: 32394292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods.
    Charidimou A; Wilson D; Shakeshaft C; Ambler G; White M; Cohen H; Yousry T; Al-Shahi Salman R; Lip G; Houlden H; Jäger HR; Brown MM; Werring DJ
    Int J Stroke; 2015 Oct; 10 Suppl A100():155-61. PubMed ID: 26235450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses.
    Yamashita T; Koretsune Y; Nagao T; Shiosakai K
    J Arrhythm; 2020 Jun; 36(3):395-405. PubMed ID: 32528563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticoagulant management by low-dose of low molecular weight heparin in patients with nonvalvular atrial fibrillation following hemorrhagic transformation and complicated with venous thrombosis: Five case reports and literature review.
    Zhang L; Kong YH; Wang DW; Li KT; Yu HP
    Medicine (Baltimore); 2021 Feb; 100(7):e24189. PubMed ID: 33607764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
    Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database.
    Khachatryan A; Doobaree IU; Spentzouris G; Gusto G; Zawaneh Y; Mughal F; Anastassopoulou A; Manu M; Fay M
    Adv Ther; 2023 Feb; 40(2):504-520. PubMed ID: 36399317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.